NYVAC-HIV-PT1 vaccine (NIAID) | Interleukin Related interleukin-related.com

Product Name :
NYVAC-HIV-PT1 vaccine (NIAID)

Search keywords :
PT1

drugId :
null

Target Vo:
Not applicable

Target Vo Short Name :
Not applicable

Moa_Name:
Immunostimulants

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
National Institute Of Allergy And Infectious Diseases (Niaid)

Active Company_Name :

Active Indication_Name:

In Active Indication_Name:
HIV Infections

Termination Status :
Phase 1 Clinical

China Termination Status :

Highest Status:
Discontinued

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Phospho-FAK (Tyr576) Antibody
RNA Polymerase II Subunit B1 Antibody
CD163 Antibody: CD163 Antibody is an unconjugated, approximately 130 kDa, rabbit-derived, anti-CD163 polyclonal antibody. CD163 Antibody can be used for: WB, ELISA, IHC-P, IHC-F, Flow-Cyt, ICC, IF expriments in human, mouse, and predicted: rat, dog, pig, horse background without labeling.

Author: Interleukin Related

Related Posts